Cure My Disease

Don't miss your cure!

 Log in / Sign up

Large french study tracks regorafenib use in Tough-to-Treat colorectal cancer

NCT ID NCT02310477

Completed Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 704 adults with metastatic colorectal cancer who received regorafenib through a French compassionate-use program. Researchers measured how long patients lived after starting the drug and collected data on tumor characteristics and prior treatments. The goal was to see how regorafenib performs in real-world settings outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
regorafenib (Stivarga)
What this could lead to
If successful, this study could confirm how well regorafenib works in everyday practice for advanced colorectal cancer patients who have run out of other options.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not test a new treatment or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

  • Centre Oscar Lambret

    Lille, 59020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.